Immunitas Therapeutics
A clinical-stage precision immunotherapy company developing novel, differentiated therapeutics for patients with cancer.
The company was founded by Longwood Fund with leading scientists from Dana-Farber, MGH, the Broad, and MIT. Since its founding in 2019, Immunitas has raised a total of $97 million in venture funding from a strong syndicate of investors including Agent Capital, Alexandria Venture Investments, Evotec, Leaps by Bayer, Longwood Fund, M Ventures, Medical Excellence Capital, and Novartis Venture Fund.
Latest Immunitas Therapeutics News & Features
18 January 2024
21 November 2019
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze